Yes, targeting MDSCs is a promising strategy in cancer therapy. Approaches include: - Inhibiting MDSC recruitment to the tumor microenvironment. - Blocking their immunosuppressive functions. - Promoting their differentiation into mature myeloid cells that do not suppress the immune system. Several drugs and compounds are being investigated for their ability to modulate MDSC activity.
